Human herpesviruses are large, enveloped viruses belonging to the family Herpesviridae. Their linear double-stranded DNA genomes are enclosed within an icosahedral capsid, surrounded by a protein-rich tegument layer and a lipid envelope containing viral glycoproteins. A defining feature of herpesviruses is their ability to establish lifelong latent infection following primary exposure and to reactivate when host immunity is altered.
Nine herpesviruses are recognized as important human pathogens, including herpes simplex virus type 1 and type 2, varicella-zoster virus, Epstein–Barr virus, human cytomegalovirus, human herpesvirus 6A and 6B, human herpesvirus 7, and Kaposi sarcoma-associated herpesvirus. These viruses differ in cellular tropism and disease association but share conserved mechanisms of genome replication, capsid assembly, membrane fusion, immune evasion, latency, and reactivation.
Representative herpesvirus structure illustrated using Epstein–Barr virus.
Major Human Herpesviruses
• HSV-1 and HSV-2: Associated primarily with oral, genital, ocular, and neurological infections
• Varicella-Zoster Virus (VZV/HHV-3): Causes chickenpox and may reactivate as shingles
• Epstein–Barr Virus (EBV/HHV-4): Associated with infectious mononucleosis and several lymphoid and epithelial malignancies
• Human Cytomegalovirus (HCMV/HHV-5): An important cause of congenital infection and disease in immunocompromised individuals
• HHV-6A, HHV-6B, and HHV-7: Lymphotropic viruses associated with childhood infection, latency, and reactivation
• Kaposi Sarcoma-Associated Herpesvirus (KSHV/HHV-8): Linked to Kaposi sarcoma and other lymphoproliferative diseases
Herpesvirus Entry and Envelope Glycoproteins
Herpesvirus entry is mediated by coordinated interactions among multiple envelope glycoproteins. In HSV-1 and HSV-2, glycoprotein D (gD) binds cellular entry receptors and activates the conserved fusion machinery formed by gH/gL and gB. Additional glycoproteins, including gC, gE, and gG, contribute to viral attachment, cell-to-cell spread, immune modulation, and type-specific antigenicity.
Epstein–Barr virus uses distinct envelope glycoprotein complexes to infect B cells and epithelial cells. The viral gp350 protein promotes attachment to B cells by binding CD21 or CD35, while the conserved gH/gL and gB proteins form the core membrane-fusion machinery required for infection of both B cells and epithelial cells.
For B-cell entry, gp42 associates with gH/gL to form the gH/gL/gp42 heterotrimer. The gp42 component binds HLA class II molecules on the B-cell surface, creating a receptor-binding and fusion-triggering complex that activates gB-mediated fusion of the viral and cellular membranes. The gH/gL/gp42 complex is therefore a major determinant of EBV B-cell tropism and an important target for neutralizing antibodies, therapeutic development, and vaccine research.
EBV entry into epithelial cells primarily depends on gH/gL and gB without gp42. Consequently, the relative abundance of gH/gL and gH/gL/gp42 complexes on the viral envelope helps regulate EBV tropism for epithelial cells versus B cells. These glycoproteins and complexes are valuable research targets for studying receptor recognition, membrane fusion, viral transmission, and protective antibody responses.
Recent Advances in Herpesvirus Research
Current HSV research is advancing beyond conventional nucleoside analog therapies toward approaches that target viral entry, immune evasion, and latent viral genomes. Investigational vaccine platforms include mRNA, protein-subunit, live-attenuated, and replication-defective candidates designed either to prevent infection or to reduce recurrences and viral shedding. At present, no HSV vaccine has been approved for clinical use.
Latency-directed research is also exploring gene-editing systems capable of disrupting HSV genomes within sensory neurons. Preclinical studies using virus-specific meganucleases delivered by viral vectors have reduced latent viral DNA and recurrent shedding in animal models, although these approaches remain experimental and require further safety and clinical evaluation.
Genetically modified HSV-1 is also being developed as an oncolytic platform for cancer treatment. These engineered viruses selectively replicate in tumor cells, promote tumor-cell destruction, and stimulate antitumor immune responses. Research on EBV increasingly focuses on multivalent vaccine antigens and antibody combinations that target gp350, gH/gL, gH/gL/gp42, and gB to inhibit infection of both B cells and epithelial cells.
Herpesvirus Research Products
eEnzyme provides recombinant herpesvirus envelope proteins, glycoprotein complexes, and antibodies for studying viral entry, antigen recognition, membrane fusion, immune responses, and diagnostic assay development. The current portfolio includes products for HSV-1, HSV-2, Epstein–Barr virus, and human cytomegalovirus.
• HSV-1 and HSV-2 recombinant glycoproteins: gB, gC, gD, gE, gG, and gH
• HSV monoclonal antibodies: Antibodies recognizing gB, gC, gD, gG, and gH/gL complexes
• HSV polyclonal antibodies: Antibodies for detection and characterization of HSV glycoproteins
• EBV recombinant proteins and complexes: gp350, gp42, gH, gH/gL, gH/gp42, and the B-cell entry complex gH/gL/gp42
• EBV monoclonal antibodies: Antibodies recognizing gH/gL and gH/gL/gp42 complexes
• Cytomegalovirus antibodies: Reagents for viral antigen detection and immunological research
Applications
• Herpesvirus entry and membrane-fusion studies
• Neutralizing antibody discovery and characterization
• Vaccine antigen research and immune-response evaluation
• EBV B-cell and epithelial-cell tropism studies
• Envelope glycoprotein and receptor interaction studies
• ELISA, Western blotting, and immunological assay development
• Epitope mapping and antigenicity analysis
• Diagnostic reagent development
• Antiviral drug discovery and therapeutic research
Research Use Only: These products are intended for laboratory research and are not intended for human or veterinary diagnostic, therapeutic, or clinical use.